Invitris is the first company to receive €250,000 from the non-profit organization Incate (Incubator for Antibacterial Therapies in Europe) for Phase II financing. With these funds, the Munich-based biotech company can develop its spin-off from the Chair of Physics of Synthetic Biological Systems at the Technical University of Munich (TUM) The Invitris Managing Director, Patrick Grossmann, says:
"Without Incate, we wouldn't have been so well prepared for the transfer from the academic environment. Being selected as the first team to win Phase II confirms our potential to build a successful company."
Invitris aims to expand the fight against antibiotic-resistant infections
The Munich-based startup had already been awarded the Incate Phase I project in January 2022. Since then, the team has been able to conduct further key experiments to minimize risk in basic research and open a new laboratory. Invitris has a platform technology for the production of synthetic proteins, so-called phages, which can be adapted to the respective disease and thus particularly effectively eliminate multidrug-resistant germs.
The next financing step is intended to help the biotech company further develop and scale its technology. Hideki Maki, Member of the Incate-selection committee and senior scientist at a drug research laboratory, says:
“We hope that Invitris will make a decisive contribution to bringing phage therapeutics into widespread use.”
